newsfilter
← Latest News
PR Newswire·

Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements

Initial Phase 1 SYSA1801 (EO-3021) data presented by partner CSPC Pharmaceutical Group Limited at ASCO 2023 showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer